A Single-center, Randomized Open-label, Single-dose, Parallel Group Study to Investigate the Relative Bioavailability of a High Concentration Liquid Formulation (Hclf) in Prefilled Syringes Versus the Reference Lyophilized Formulation (Lyof) of Gantenerumab Following Administration by Subcutaneous Injection in Healthy Volunteers

Trial Profile

A Single-center, Randomized Open-label, Single-dose, Parallel Group Study to Investigate the Relative Bioavailability of a High Concentration Liquid Formulation (Hclf) in Prefilled Syringes Versus the Reference Lyophilized Formulation (Lyof) of Gantenerumab Following Administration by Subcutaneous Injection in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2015

At a glance

  • Drugs Gantenerumab (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 12 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top